Sentences with phrase «vaccine development work»
And a new analysis of the STEP trial, published last November in Proceedings of the National Academy of Sciences USA, provides a warning that the very vectors (adenoviruses, which are also employed in other vaccine development work) used to distribute the inactive HIV strains can actually make the immune system more vulnerable to infection by recruiting susceptible T cells to mucous membranes, where they are more likely to be infected during sexual activity.
https://www.scientificamerican.com/ Not exact matches
Kim co-founded VGX Pharmaceuticals about 15 years ago, after working in vaccine development for Merck.
«Understanding the fundamental biology of how our immune system works will lead to the development of more effective drugs and vaccines,» said Kanneganti, corresponding author on the paper.
Half of tenOever's lab now works in bioengineering and vaccine development.
To fund the new approach to the work, tenOever contacted the Army Research Office, which sponsors new technology for vaccine development.
Contributing to work on smallpox, polio, and vaccine development, primates allow research on potential treatments for hepatitis C and B, Ebola and Marburg viruses, and HIV / AIDS.
The incoming AAAS Public Engagement Fellows work in such varied disciplines as virology, vaccine and pharmaceutical development, public health, demography, disease ecology, environmental health, parasitology, and human and veterinary epidemiology.
«The biggest issue will be price,» says John Schiller, a senior investigator at the National Cancer Institute, who did some of the early work that led to the vaccine's development.
Companies in the consortium locate postdocs at universities and offer them funding to work on industry projects in such areas as nanobiotechnology, marine biotechnology, and vaccine development.
Ebola vaccine for chimps works but may never be used Chimpanzees threatened by an Ebola outbreak could be protected by a new vaccine, but cuts in chimp research may stymie its development
«It's probably the furthest along in development of the prophylactic vaccines, but a lot of us don't think such a vaccine will work so well,» says Jake Liang at the National Institute of Diabetes and Digestive and Kidney Diseases.
WRAIR is working on the vaccine in collaboration with other U.S. government agencies, including the NIAID, part of the National Institutes of Health, and the Biomedical Advanced Research and Development Authority, part of the Department of Health and Human Services.
Col. Nelson Michael, the WRAIR Zika program co-lead, said, «This critical first step has informed our ongoing work in non-human primates and gives us early confidence that development of a protective Zika virus vaccine for humans is feasible.»
Traditional methods of vaccine development, such as rendering a pathogen harmless and injecting it, do not work.
Now, however, the pioneering vaccine development project has ended, and MVP and partners are working with African government health officials to carefully plan for the next steps in the continued deployment of MenAfriVac ®.
«In addition to how well a vaccine works to protect against disease, safety is another important aspect for vaccine development,» said Chopra.
In Australia, researchers have been working on a chlamydia vaccine for koalas, which may also be a step towards development of a human vaccine.
They supported a range of studies, from work on gene therapy tools (including adenovirus and rous sarcoma virus vectors) to development of a new vaccine for the deadly Marburg virus.
The work defines a new type of virus structure, and it could spur the development of drugs and vaccines to stop dengue fever and related mosquito - and tick - borne diseases.
Batista was one of a number of scientists involved in the study from the Ragon Institute, established in the Boston area by experts from Massachusetts General Hospital, Harvard University and the Massachusetts Institute of Technology, with the goal of working toward development of an effective vaccine against HIV / AIDS.
Working with a world - leading group at the University of Connecticut in the USA, who pioneered the development of self - assembling protein nanoparticles (SAPNs) for vaccine design, they have used advanced mathematical calculations to create a complete picture of the surface morphology of these particles.
She was responsible for the development of several new vaccines currently undergoing clinical trials and also has experience as a work package leader within large international consortia.
The project is a joint effort of leading European groups working in the field of vaccine development, and is coordinated by the European Vaccine Initiativevaccine development, and is coordinated by the European Vaccine InitiativeVaccine Initiative (EVI).
Within the Joint Research Activity (JRA3) Assay development and validation, Fraunhofer will work on the development and standardization of SPR - methods required during vaccine research and development as well as production and quality control, and on the development of impurity - related assays required for product characterization.
This understanding of how HIV - 1's «invisibility cloak» works could lead to the development of effective vaccines against HIV - 1.
Previously, Torsten worked for more than 10 years at GlaxoSmithKline Vaccines where he was the Global Head of the Vaccines Transactions Team with responsibility for all vaccine business development activities ranging from collaborations, option and licensing contracts to mergers & acquisitions.
We are leaders in the field of cancer immunotherapy and the development of tumor vaccines and new antibodies, working to activate the human body's own immune system to fight cancer.
The development of a safe and effective vaccine takes many years and needs to go through many different stages of testing, including work on cells, testing on animals and finally clinical trials on humans.
«This is an exciting development, but the new vaccines now need to be tested in clinical trials to see how well they work in humans.
Her work has unraveled the intricacies of how viruses evade the human immune system and uncovered molecular targets for the development of drugs and vaccines for a range of infectious diseases.
This work will increase our knowledge of the virulence of this understudied biothreat pathogen and provide a foundation for the development of diagnostic and therapeutic countermeasures and a protective vaccine for melioidosis.
His work has led to the development of two potential malaria vaccines, one of which is in clinical trials in the US and the other in preclinical development.
His work centers on new immunomodulatory agents and formulations, as well as the process development necessary to take vaccines and therapeutic candidates from the lab to the clinic.
Dr. Baldwin has been at IDRI for over six years and currently works on projects related to development of next - generation vaccines against infectious diseases.
Before joining IDRI, Tracey worked as a Protocol Development Manager with the HIV Vaccine Trials Network at the Fred Hutchinson Cancer Research Center where she led multi-disciplinary teams in the design and implementation of clinical trials evaluating candidate HIV and tuberculosis vaccines.
UNC School of Medicine's Aravinda de Silva, PhD, who is currently working on NIH - funded Zika vaccine development and other Zika research, is a co-author.
She completed her doctorate work in Dr. Ian Orme's laboratory where she focused on the development of several novel vaccines against M. tuberculosis.
Stacey is a postdoctoral scientist in the Formulations group at IDRI, currently working on adjuvant development and vaccine formulation.
Farokhzad and colleagues have considerable expertise with bench - to - bedside translation of nanotechnologies for medical applications, and foundational work done in part by his team has led to the development and first in human testing of a targeted nanoparticle capable of controlling drug release for treatment of cancers, and the first in human testing of a targeted nanoparticle vaccine capable of orchestrating an immune response to facilitate smoking cessation and relapse prevention.
Research Focus: Since 2008, I have been working as a Scientific Curator for the IEDB project, a globally - utilized bioinformatics research tool to aid development of vaccines, immunotherapeutics, and diagnostics.
Afterwards, Tom spent two years working at LigoCyte pharmaceuticals, where he served as Director of Process Development and Project Leader in the Norovirus vaccine program.
Moving the Needle provides quarterly updates from PATH's Center for Vaccine Innovation and Access (CVIA) on our vaccine development efforts, as well as related supporting work, such as developing human challenge models, building capacity of developing - country vaccine manufacturers, and evaluating new adjuvants and other novel vaccine technoVaccine Innovation and Access (CVIA) on our vaccine development efforts, as well as related supporting work, such as developing human challenge models, building capacity of developing - country vaccine manufacturers, and evaluating new adjuvants and other novel vaccine technovaccine development efforts, as well as related supporting work, such as developing human challenge models, building capacity of developing - country vaccine manufacturers, and evaluating new adjuvants and other novel vaccine technovaccine manufacturers, and evaluating new adjuvants and other novel vaccine technovaccine technologies.
Vaccine and other prevention products» development often works that way, but there can be more to it.
The lab is currently a part of a multi-institutional group working on developing a prophylactic HIV vaccine under a five year Integrated Preclinical / Clinical AIDS Vaccine Development Program grant from the National Institutes of Allergy and Infectious Disease (vaccine under a five year Integrated Preclinical / Clinical AIDS Vaccine Development Program grant from the National Institutes of Allergy and Infectious Disease (Vaccine Development Program grant from the National Institutes of Allergy and Infectious Disease (NIAID).
A vast amount of very good scientific work has been completed on the biology of HIV and the various avenues open for vaccine development.
He then held a postdoctoral position for five years at Nijmegen University, where he worked on malaria transmission - blocking vaccine development.
This image shows how the new vaccine under development works.
In September of the same year, he moved to Novartis Vaccines and Diagnostic in Siena (Italy), where he devoted his work on structural characterization of protein - based constructs for the development of a polyvalent vaccine against meningococcal meningitis.
She has worked in vaccinology for 40 years, and has contributed to the development of synthetic adjuvants and peptidic vaccines and of several innovative delivery systems and cancer vaccines.
Research & Development IAVI worked with the Japanese biotech company DNAVEC, based in Tsukuba City, to jointly develop an AIDS vaccine candidate based on its novel Sendai vector technology.